-+ 0.00%
-+ 0.00%
-+ 0.00%
Summit Therapeutics Initiates Global Phase III Clinical Trial Of Ivonescimab In Non-Small Cell Lung Cancer; Expects Global Clinical Trial Site Activations For HARMONi-10 To Begin In Q4 2026
Share
Listen to the news

The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Consolidation therapy, given after a patient has responded to initial treatment, aims to deepen or prolong that response and delay or prevent the cancer from coming back or progressing.

HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3, and HARMONi-7. The study extends Summit’s global clinical development program into the locally advanced, unresectable setting, where durvalumab, following curative-intent chemoradiation, is a current standard of care.

HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III clinical trial. The primary endpoint of the study is progression-free survival (PFS). Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending